StockWaves
  • Home
  • Global Markets
    Global MarketsShow More
    NVDA Earnings: Nvidia Q3 FY26 income and revenue beat estimates
    NVDA Earnings: Nvidia Q3 FY26 income and revenue beat estimates
    1 Min Read
    Because the FTSE falls I can see low-cost shares in every single place – time to buy groceries!
    Because the FTSE falls I can see low-cost shares in every single place – time to buy groceries!
    4 Min Read
    Copart Q1 2026 Earnings Preview
    Copart Q1 2026 Earnings Preview
    0 Min Read
    Nvidia (NVDA) earnings report Q3 2026
    Nvidia (NVDA) earnings report Q3 2026
    5 Min Read
    Many Fed policymakers finally assembly had been against December fee lower
    Many Fed policymakers finally assembly had been against December fee lower
    0 Min Read
  • Investment Strategies
    Investment StrategiesShow More
    Are particular alternative funds actually "particular"?
    Are particular alternative funds actually "particular"?
    0 Min Read
    Time is your most worthwhile funding
    Time is your most worthwhile funding
    0 Min Read
    Methods to Spot “Hidden” Development Shares in 2025
    Methods to Spot “Hidden” Development Shares in 2025
    5 Min Read
    How these 3 small caps turned ₹1L into ₹10-46L in 5 years
    How these 3 small caps turned ₹1L into ₹10-46L in 5 years
    0 Min Read
    A brand new flexi-cap whose returns are 3x greater than its rivals
    A brand new flexi-cap whose returns are 3x greater than its rivals
    0 Min Read
  • Market Analysis
    Market AnalysisShow More
    Sebi provides mutual fund homes extra time as debate intensifies over charge caps
    Sebi provides mutual fund homes extra time as debate intensifies over charge caps
    3 Min Read
    Debt's wild baby returns
    Debt's wild baby returns
    0 Min Read
    Soybean futures ease from 17-month peak as merchants gauge China shopping for tempo
    Soybean futures ease from 17-month peak as merchants gauge China shopping for tempo
    3 Min Read
    Meet the market-beating minds
    Meet the market-beating minds
    0 Min Read
    BlackRock’s 5 billion plan to extend fairness publicity fuels AI, tech inventory bets
    BlackRock’s $185 billion plan to extend fairness publicity fuels AI, tech inventory bets
    4 Min Read
  • Trading
    TradingShow More
    Dan Loeb Raises Microsoft Stake 175% In Large-Tech Push, Dumps Workday And Extra (CORRECTED) – Apollo Asset Administration (NYSE:APO), Amazon.com (NASDAQ:AMZN)
    Dan Loeb Raises Microsoft Stake 175% In Large-Tech Push, Dumps Workday And Extra (CORRECTED) – Apollo Asset Administration (NYSE:APO), Amazon.com (NASDAQ:AMZN)
    2 Min Read
    Choices Nook: Profiting From The ‘Hidden Geometry’ Of SoFi Applied sciences – SoFi Applied sciences (NASDAQ:SOFI)
    Choices Nook: Profiting From The ‘Hidden Geometry’ Of SoFi Applied sciences – SoFi Applied sciences (NASDAQ:SOFI)
    8 Min Read
    Newbie’s Information to Choosing the Most Dependable Martingale EA for MT4
    Newbie’s Information to Choosing the Most Dependable Martingale EA for MT4
    11 Min Read
    Why Is Freeport-McMoRan Inventory Gaining Wednesday? – Freeport-McMoRan (NYSE:FCX)
    Why Is Freeport-McMoRan Inventory Gaining Wednesday? – Freeport-McMoRan (NYSE:FCX)
    3 Min Read
    Broadcom Unveils New ‘Gen 8’ Tech Designed To Defend In opposition to Future Quantum Cyberattacks – Broadcom (NASDAQ:AVGO)
    Broadcom Unveils New ‘Gen 8’ Tech Designed To Defend In opposition to Future Quantum Cyberattacks – Broadcom (NASDAQ:AVGO)
    3 Min Read
Reading: Anthem Biosciences IPO Overview – Dates, Worth, GMP, Evaluation
Share
Font ResizerAa
StockWavesStockWaves
  • Home
  • Global Markets
  • Investment Strategies
  • Market Analysis
  • Trading
Search
  • Home
  • Global Markets
  • Investment Strategies
  • Market Analysis
  • Trading
Follow US
2024 © StockWaves.in. All Rights Reserved.
StockWaves > Investment Strategies > Anthem Biosciences IPO Overview – Dates, Worth, GMP, Evaluation
Investment Strategies

Anthem Biosciences IPO Overview – Dates, Worth, GMP, Evaluation

StockWaves By StockWaves Last updated: July 14, 2025 7 Min Read
Anthem Biosciences IPO Overview – Dates, Worth, GMP, Evaluation
SHARE


Contents
About Anthem Biosciences LtdAnthem Biosciences IPO Subject ParticularsFinancials of Anthem BiosciencesP/E Ratio and Peer ComparabilityObjects of the SubjectGray Market Premium (GMP) of Anthem Biosciences IPOCauses to Put money into Anthem Biosciences IPOThreat ComponentsMethods to Apply for Anthem Biosciences IPO?Conclusion: Must you Subscribe to Anthem Biosciences IPO or Keep away from?FAQs on Anthem Biosciences IPOUncover extra from Myinvestmentideas.com

Introduction to Anthem Biosciences IPO

Anthem Biosciences Restricted is arising with its Preliminary Public Providing (IPO) which opens for subscription on July 14, 2025 and closes on July 16, 2025. The IPO is solely an Supply for Sale (OFS) of 5.96 crore shares, aggregating as much as ₹ 3,395 crore. The corporate is not going to obtain any proceeds from this difficulty. This IPO is drawing consideration because of its sturdy presence within the Contract Analysis, Improvement, and Manufacturing Group (CRDMO) house. On this article we might analyse and evaluate Anthem Biosciences IPO, Particulars, IPO Dates, Threat Components, Causes to speculate, GMP, Valuations and supply our view about this IPO.

About Anthem Biosciences Ltd

Included in 2006, Anthem Biosciences is a technology-driven CRDMO providing end-to-end options throughout drug discovery, improvement, and manufacturing. It supplies specialised fermentation-based APIs, probiotics, enzymes, peptides, and biosimilars to world purchasers in over 44 nations.

The corporate had 196 energetic tasks as of September 30, 2024, and a powerful buyer base together with over 550 purchasers, starting from rising biotech to massive pharma firms.

Anthem Biosciences IPO Overview – Dates, Worth, GMP, Evaluation

Aggressive Strengths

  • Absolutely built-in CRDMO with presence throughout the drug life cycle.
  • Concentrate on innovation with sturdy patent portfolio (7 abroad, 1 India, 24 pending).
  • Sturdy world consumer base throughout 44+ nations.
  • Skilled administration and strong R&D group (600+ scientists).
  • Diversified income from CRDMO and specialty components companies.

Anthem Biosciences IPO Subject Particulars

  • IPO Opening Date: July 14, 2025
  • IPO Closing Date: July 16, 2025
  • Itemizing Date: July 21, 2025 (Tentative)
  • Worth Band: ₹ 540 – ₹ 570 per share
  • Lot Dimension: 26 shares
  • Minimal Funding: ₹ 14,820
  • Worker Low cost: ₹ 50/share
  • Complete Subject Dimension: ₹ 3,395 crore (OFS solely)
  • Itemizing At: BSE and NSE

Financials of Anthem Biosciences

ParticularsFY23FY24FY25
Income (Cr)1,133.991,483.071,930.29
PAT (Cr)385.19367.31451.26
EBITDA (Cr)446.05519.96683.78
Internet Price (Cr)1,740.671,924.662,409.86
ROE––20.82%
ROCE––26.88%
PAT Margin––23.38%
EBITDA Margin––36.81%
Debt/Fairness––0.05

P/E Ratio and Peer Comparability

  • EPS (FY25): ₹ 8.07
  • P/E at higher worth band (₹ 570): ~70.62x

Friends: Most listed CRDMO firms in India commerce at excessive P/E because of restricted provide and world demand. Nevertheless, a P/E over 70x for this IPO suggests aggressive pricing.

Objects of the Subject

This IPO is an entire Supply for Sale, and no proceeds will go to the corporate. The whole quantity will likely be obtained by promoting shareholders.

Gray Market Premium (GMP) of Anthem Biosciences IPO

As of newest updates, the GMP is round ₹ 110-130, indicating a possible itemizing acquire of 20-23% over the higher band worth.

Causes to Put money into Anthem Biosciences IPO

  • One in all India’s main CRDMO gamers.
  • Sturdy income and revenue development.
  • Low debt (D/E of 0.05), excessive ROE and ROCE.
  • Diversified world consumer base.
  • Possible itemizing good points as per present GMP.

Threat Components

  • Solely an OFS; firm received’t obtain funds.
  • Premium valuation with P/E ~70x.
  • Excessive dependency on worldwide purchasers.
  • Regulatory dangers associated to pharma manufacturing.
  • No long-term steerage offered.

Methods to Apply for Anthem Biosciences IPO?

Traders can apply through:

  • Internet banking utilizing ASBA (beneath IPO part)
  • UPI by way of dealer platforms like Zerodha, Groww, Upstox

Guarantee UPI mandate is permitted earlier than 5 PM on July 16, 2025.

Conclusion: Must you Subscribe to Anthem Biosciences IPO or Keep away from?

Anthem Biosciences has proven sturdy monetary development and instructions a distinct segment place within the CRDMO house. Whereas the valuation seems premium, the strong fundamentals and powerful GMP counsel optimistic itemizing potential. Excessive-risk buyers with long-term view can Subscribe to this IPO. Conservative buyers might look forward to post-listing alternatives.

FAQs on Anthem Biosciences IPO

  1. What’s the Anthem Biosciences IPO date?
  • The IPO opens on July 14, 2025, and closes on July 16, 2025.
  1. What’s the Anthem Biosciences IPO worth band?
  • The worth band is ₹ 540 to ₹ 570 per share.
  1. What’s the minimal lot dimension for Anthem Biosciences IPO?
  • Minimal lot is 26 shares, which quantities to ₹ 14,820.
  1. What’s the GMP of Anthem Biosciences IPO?
  • As per the most recent, GMP is round ₹ 110-130.
  1. Is Anthem Biosciences IPO good for funding?
  • It’s appropriate for high-risk buyers searching for long-term development within the biotech and pharma house.
  1. How a lot is the IPO dimension and construction?
  • IPO dimension is ₹ 3,395 crore, and it’s a 100% Supply for Sale.
  1. When will Anthem Biosciences IPO be listed?
  • Tentative itemizing date is July 21, 2025 on BSE and NSE.

Disclaimer: This text is for informational functions solely and never a advice or solicitation to purchase or promote any securities. The IPO evaluate is predicated on data accessible within the Pink Herring Prospectus (RHP) and different dependable sources on the time of writing. Readers are suggested to seek the advice of their monetary advisor earlier than making any funding determination. Myinvestmentideas.com or the writer just isn’t answerable for any losses incurred based mostly on this data.

Suresh KPSuresh KP
Suresh KP is a seasoned monetary knowledgeable with over 20 years of expertise. He’s NISM Licensed Funding Adviser and Analysis Analyst. For extra about his experience and certifications, go to About Suresh KP
Suresh KPSuresh KP
Newest posts by Suresh KP (see all)


Uncover extra from Myinvestmentideas.com

Subscribe to get the most recent posts despatched to your e mail.

Sign Up For Daily Newsletter

Be keep up! Get the latest breaking news delivered straight to your inbox.

By signing up, you agree to our Terms of Use and acknowledge the data practices in our Privacy Policy. You may unsubscribe at any time.
Share This Article
Facebook Twitter Copy Link Print
Previous Article Q1 outcomes 2025: Reliance Ind, HCL Tech, HDFC Financial institution, Wipro amongst corporations to declare earnings this week; test full record Q1 outcomes 2025: Reliance Ind, HCL Tech, HDFC Financial institution, Wipro amongst corporations to declare earnings this week; test full record
Next Article Japan’s Could industrial output revised all the way down to 0.1% fall Japan’s Could industrial output revised all the way down to 0.1% fall
Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

FacebookLike
TwitterFollow
PinterestPin
InstagramFollow

Subscribe Now

Subscribe to our newsletter to get our newest articles instantly!

Most Popular
Tectum Publicizes Launch of Tectum Money Token (TCT) Forward of December Alternate Listings
Tectum Publicizes Launch of Tectum Money Token (TCT) Forward of December Alternate Listings
November 20, 2025
PM Modi to attend G20 Summit in Jo’burg this week, additionally take part in IBSA assembly
PM Modi to attend G20 Summit in Jo’burg this week, additionally take part in IBSA assembly
November 20, 2025
US shares edge greater as Nvidia check looms
US shares edge greater as Nvidia check looms
November 20, 2025
NVDA Earnings: Nvidia Q3 FY26 income and revenue beat estimates
NVDA Earnings: Nvidia Q3 FY26 income and revenue beat estimates
November 20, 2025
Sebi provides mutual fund homes extra time as debate intensifies over charge caps
Sebi provides mutual fund homes extra time as debate intensifies over charge caps
November 20, 2025

You Might Also Like

Greatest pet enterprise concepts to make thousands and thousands
Investment Strategies

Greatest pet enterprise concepts to make thousands and thousands

12 Min Read
Fail quick, fail low cost
Investment Strategies

Fail quick, fail low cost

0 Min Read
IRFC share value climbs 4% regardless of a 2% dip in This autumn revenue
Investment Strategies

IRFC share value climbs 4% regardless of a 2% dip in This autumn revenue

0 Min Read
Fund supervisor adjustments within the  Nippon India Revenue Plus Arbitrage Energetic FoF
Investment Strategies

Fund supervisor adjustments within the Nippon India Revenue Plus Arbitrage Energetic FoF

0 Min Read

Always Stay Up to Date

Subscribe to our newsletter to get our newest articles instantly!

StockWaves

We provide tips, tricks, and advice for improving websites and doing better search.

Latest News

  • About Us
  • Contact Us
  • Privacy Policy
  • Terms Of Service

Resouce

  • Blockchain
  • Business
  • Economics
  • Financial News
  • Global Markets
  • Investment Strategies
  • Market Analysis
  • Trading

Trending

Tectum Publicizes Launch of Tectum Money Token (TCT) Forward of December Alternate Listings
PM Modi to attend G20 Summit in Jo’burg this week, additionally take part in IBSA assembly
US shares edge greater as Nvidia check looms

2024 © StockWaves.in. All Rights Reserved.

Welcome Back!

Sign in to your account

Not a member? Sign Up